JP6672157B2 - 肥満を処置するための化合物およびその使用方法 - Google Patents

肥満を処置するための化合物およびその使用方法 Download PDF

Info

Publication number
JP6672157B2
JP6672157B2 JP2016554826A JP2016554826A JP6672157B2 JP 6672157 B2 JP6672157 B2 JP 6672157B2 JP 2016554826 A JP2016554826 A JP 2016554826A JP 2016554826 A JP2016554826 A JP 2016554826A JP 6672157 B2 JP6672157 B2 JP 6672157B2
Authority
JP
Japan
Prior art keywords
obese
pharmaceutical formulation
administered
formulation
leptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016554826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537431A (ja
JP2016537431A5 (cg-RX-API-DMAC7.html
Inventor
ウムット オズカン，
ウムット オズカン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2016537431A publication Critical patent/JP2016537431A/ja
Publication of JP2016537431A5 publication Critical patent/JP2016537431A5/ja
Application granted granted Critical
Publication of JP6672157B2 publication Critical patent/JP6672157B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016554826A 2013-11-26 2014-11-25 肥満を処置するための化合物およびその使用方法 Active JP6672157B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908998P 2013-11-26 2013-11-26
US61/908,998 2013-11-26
PCT/US2014/067393 WO2015081093A1 (en) 2013-11-26 2014-11-25 Compounds for the treatment of obesity and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019226600A Division JP2020059744A (ja) 2013-11-26 2019-12-16 肥満を処置するための化合物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2016537431A JP2016537431A (ja) 2016-12-01
JP2016537431A5 JP2016537431A5 (cg-RX-API-DMAC7.html) 2017-11-24
JP6672157B2 true JP6672157B2 (ja) 2020-03-25

Family

ID=52134396

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016554826A Active JP6672157B2 (ja) 2013-11-26 2014-11-25 肥満を処置するための化合物およびその使用方法
JP2019226600A Pending JP2020059744A (ja) 2013-11-26 2019-12-16 肥満を処置するための化合物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019226600A Pending JP2020059744A (ja) 2013-11-26 2019-12-16 肥満を処置するための化合物およびその使用方法

Country Status (18)

Country Link
US (1) US20160375039A1 (cg-RX-API-DMAC7.html)
EP (1) EP3074033B1 (cg-RX-API-DMAC7.html)
JP (2) JP6672157B2 (cg-RX-API-DMAC7.html)
AU (2) AU2014354831B2 (cg-RX-API-DMAC7.html)
CA (1) CA2931826C (cg-RX-API-DMAC7.html)
CY (1) CY1122551T1 (cg-RX-API-DMAC7.html)
DK (1) DK3074033T3 (cg-RX-API-DMAC7.html)
ES (1) ES2709976T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190219T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042196T2 (cg-RX-API-DMAC7.html)
LT (1) LT3074033T (cg-RX-API-DMAC7.html)
PL (1) PL3074033T3 (cg-RX-API-DMAC7.html)
PT (1) PT3074033T (cg-RX-API-DMAC7.html)
RS (1) RS58422B1 (cg-RX-API-DMAC7.html)
SI (1) SI3074033T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900064T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901299T4 (cg-RX-API-DMAC7.html)
WO (1) WO2015081093A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN106008657B (zh) * 2016-05-20 2017-11-21 天津中医药大学 苦蘵苦素i及提取方法及用途
IT201800005336A1 (it) * 2018-05-14 2019-11-14 Composizioni per uso nel trattamento dell’obesità
WO2021072139A1 (en) * 2019-10-11 2021-04-15 Massachusetts Institute Of Technology Formulations for gastrointestinal delivery of oligonucleotides
CN113599502A (zh) * 2021-07-22 2021-11-05 廖儒佳 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
CA2223433C (en) 1995-06-07 2003-11-18 Amgen Inc. Ob protein compositions and methods
CZ416797A3 (cs) 1995-06-30 1998-06-17 Eli Lilly And Company Použití leptinu nebo leptonových mimetik pro výrobu léčiv pro léčení nebo prevenci diabetes mellitus a kompozice s jeho obsahem
DK0865294T3 (da) 1995-08-17 2004-06-28 Amgen Inc Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
NZ512083A (en) 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
CA2258504A1 (en) * 1996-06-20 1997-12-24 Merck & Co., Inc. Gene therapy for obesity
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法
HUP9904023A3 (en) 1996-09-20 2002-01-28 Hoechst Ag Use of leptin antagonists for treating insulin resistance in type ii diabetes
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
RS49927B (sr) 1996-12-20 2008-09-29 Amgen Inc., Preparati ob fuzionog proteina i postupci
CN1202862C (zh) 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
KR20010013414A (ko) 1997-06-06 2001-02-26 피터 기딩스 당뇨병의 치료를 위한 렙틴 길항제의 용도
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
ATE280588T1 (de) 1998-08-10 2004-11-15 Amgen Inc Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PT1151102E (pt) 1999-02-12 2006-07-31 Amgen Inc Composicoes de leptina glicosilada e metodos afins
PT2219031E (pt) 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
JP4585186B2 (ja) * 2003-07-31 2010-11-24 杏林製薬株式会社 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
PT2040755E (pt) * 2006-06-23 2011-07-08 Esteve Labor Dr Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
WO2010030395A2 (en) * 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
WO2010053655A2 (en) * 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
WO2012106393A2 (en) * 2011-02-01 2012-08-09 University Of Kansas Withanolide isolated from physalis longifolia and analogs and methods of use thereof

Also Published As

Publication number Publication date
US20160375039A1 (en) 2016-12-29
JP2016537431A (ja) 2016-12-01
AU2018200517A1 (en) 2018-02-15
PT3074033T (pt) 2019-02-08
WO2015081093A1 (en) 2015-06-04
LT3074033T (lt) 2019-02-25
TR201901299T4 (tr) 2019-02-21
EP3074033A1 (en) 2016-10-05
CA2931826C (en) 2021-11-16
AU2018200517B2 (en) 2019-12-19
JP2020059744A (ja) 2020-04-16
HUE042196T2 (hu) 2019-06-28
CY1122551T1 (el) 2021-01-27
DK3074033T3 (en) 2019-02-11
SI3074033T1 (sl) 2019-03-29
ES2709976T3 (es) 2019-04-22
EP3074033B1 (en) 2018-11-07
PL3074033T3 (pl) 2019-08-30
CA2931826A1 (en) 2015-06-04
AU2014354831B2 (en) 2017-10-26
AU2014354831A1 (en) 2016-06-09
RS58422B1 (sr) 2019-04-30
SMT201900064T1 (it) 2019-02-28
HRP20190219T1 (hr) 2019-03-22

Similar Documents

Publication Publication Date Title
US12064408B2 (en) Compounds for the treatment of obesity and methods of use thereof
JP2020059744A (ja) 肥満を処置するための化合物およびその使用方法
US20170209408A1 (en) Hsp90 inhibitors for the treatment of obesity and methods of use thereof
HK40034040A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034039A (en) Compounds for the treatment of obesity and methods of use thereof
HK40003238A (en) Compounds for the treatment of obesity and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171013

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171013

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191216

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200120

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200304

R150 Certificate of patent or registration of utility model

Ref document number: 6672157

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250